Interview with Prof. Agata Szulc, head of the Psychiatric Clinic at the Faculty of Health Sciences of the Medical University of Warsaw.
How big a change in the treatment of drug-resistant depression is the reimbursement of esketamine in the drug program?
This is certainly a big change. The drug program is governed by its own rules and it imposes some restrictions, but many patients have already asked about it. The drug is registered for this indication as of 2019, but its cost is very high and out of reach ...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
